$171.72
0.37% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Ascendis Pharma A/S Sponsored ADR Stock price

$171.72
+17.29 11.20% 1M
+37.44 27.88% 6M
+34.05 24.73% YTD
+39.79 30.16% 1Y
+30.50 21.60% 5Y
+155.63 967.25% 10Y
+152.89 811.95% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.63 0.37%
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Key metrics

Market capitalization $10.41b
Enterprise Value $10.78b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 25.46
P/S ratio (TTM) P/S ratio 24.57
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.06%
Revenue (TTM) Revenue $423.58m
EBIT (operating result TTM) EBIT $-374.89m
Free Cash Flow (TTM) Free Cash Flow $-253.73m
Cash position $595.01m
EPS (TTM) EPS $-6.54
P/E forward negative
P/S forward 14.87
EV/Sales forward 15.41
Short interest 7.47%
Show more

Is Ascendis Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.

Ascendis Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

17x Buy
100%

Analyst Opinions

17 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

Buy
100%

Financial data from Ascendis Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
424 424
12% 12%
100%
- Direct Costs 62 62
14% 14%
15%
361 361
12% 12%
85%
- Selling and Administrative Expenses 361 361
19% 19%
85%
- Research and Development Expense 358 358
15% 15%
84%
-358 -358
11% 11%
-84%
- Depreciation and Amortization 17 17
32% 32%
4%
EBIT (Operating Income) EBIT -375 -375
10% 10%
-89%
Net Profit -393 -393
32% 32%
-93%

In millions USD.

Don't miss a Thing! We will send you all news about Ascendis Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ascendis Pharma A/S Sponsored ADR Stock News

Neutral
GlobeNewsWire
3 days ago
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of T...
Neutral
GlobeNewsWire
10 days ago
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo
Neutral
Accesswire
23 days ago
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / May 20, 2025 / Cerrado Gold Inc. ("Cerrado") (TSXV:CERT)(OTCQX:CRDOF) and Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") are pleased to announce the successful completion of the previously announced plan of arrangement (the "Arrangement") unde...
More Ascendis Pharma A/S Sponsored ADR News

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Head office Denmark
CEO Jan Mikkelsen
Employees 1,017
Founded 2006
Website ascendispharma.dk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today